Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2854)	5/19/1999 4:00:00 PM
From: RCMac	Read Replies (1) \| Respond to of 10280

>> norcisapride - no QT prolongation, even at 30-40X dose of parent. "Likely to be more efficacious." J&J advancing in a "committed way." << Peter, First, thanks for your reports. Second, I'm delighted to hear the above about norcisapride, as it might well be a big, big multi-indication winner for SEPR. Did anyone give an opinion of the chances that the FDA would pull Propulsid (cisapride) from the market after FDA approval of norcisapride, as it did with Seldane following the Allegra approval? When I spoke with SEPR's Barlow last fall I asked him that about Hismanal, Propulsid and Claritin. He said he thought it pretty likely for Hismanal, no chance for Claritin, and (surprisingly to me, in light of the side effect profile) something like "probably not" for Propulsid -- these may not be the exact words, but the nuance is about right. So I'm wondering if SEPR's and JNJ's views have evolved on this point, in view of what you report. (This is of course worth a lot of money to SEPR and JNJ, since pulling Propulsid would prevent the generic competition that is otherwise inevitable once Propulsid's patent protection expires.) --RCM